Clinical implications of cytomegalovirus in glioblastoma progression and therapy
Abstract Glioblastoma (GBM) is one of the deadliest brain cancers with a median survival of only 15 months.This poor prognosis has prompted exploration of novel therapeutic targets for GBM patients.Human cytomegalovirus (HCMV) has been implicated in GBM; however, its impact remains poorly defined, and there is conflicting data over the presence of